March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Spero Therapeutics
(NASDAQ:SPRO)
Intraday
$1.7007
-0.0493
[-2.82%]
After-Hours
$1.7007
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$1.7007
-0.0493
[-2.82%]
At close: Mar 28
$1.7007
0
[0.00%]
After Hours: 5:09PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Spero Therapeutics Stock (NASDAQ:SPRO)
Spero Therapeutics Stock (NASDAQ: SPRO)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 18, 2024
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Mar 18, 2024, 7:02AM
Thursday, March 14, 2024
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Mar 14, 2024, 1:38PM
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Mar 14, 2024, 8:05AM
Spero Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Mar 14, 2024, 8:04AM
Wednesday, March 13, 2024
Recap: Spero Therapeutics Q4 Earnings
Benzinga Insights
-
Mar 13, 2024, 4:15PM
Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate
Benzinga Newsdesk
-
Mar 13, 2024, 4:12PM
Earnings Scheduled For March 13, 2024
Benzinga Insights
-
Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Earnings Outlook For Spero Therapeutics
Benzinga Insights
-
Mar 12, 2024, 1:01PM
Wednesday, February 28, 2024
Spero Therapeutics Announces Clearance Of IND For SPR206 To Treat MDR Gram-Negative Bacterial Infections
Benzinga Newsdesk
-
Feb 28, 2024, 8:08AM
Friday, January 05, 2024
Spero Therapeutics Expects To Provide Phase 2a Topline Proof Of Concept Data From SPR720 Program; Co. Also Initiated Dosing In PIVOT-PO Phase 3 Trial And Is Entitled To Receive $95M In Milestones As Part Of License Agreement
Benzinga Newsdesk
-
Jan 5, 2024, 8:11AM
Tuesday, January 02, 2024
Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years
Benzinga Newsdesk
-
Jan 2, 2024, 8:07AM
Monday, December 04, 2023
5 Value Stocks In The Healthcare Sector
Benzinga Insights
-
Dec 4, 2023, 9:44AM
Tuesday, November 14, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Nov 14, 2023, 4:31PM
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Nov 14, 2023, 6:31AM
Monday, November 13, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Nov 13, 2023, 4:31PM
Recap: Spero Therapeutics Q3 Earnings
Benzinga Insights
-
Nov 13, 2023, 4:20PM
Spero Therapeutics Q3 EPS $(0.06) Misses $(0.03) Estimate, Sales $25.47M Beat $14.97M Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 4:19PM
Earnings Scheduled For November 13, 2023
Benzinga Insights
-
Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Earnings Outlook For Spero Therapeutics
Benzinga Insights
-
Nov 10, 2023, 12:02PM
Wednesday, November 01, 2023
Spero Therapeutics Has Appointed Esther Rajavelu As CFO And Chief Business Officer, Succeeding Stephen Dipalma, Who Has Served As The Company's Interim CFO Since August 1, 2023
Benzinga Newsdesk
-
Nov 1, 2023, 8:13AM
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Oct 4, 2023, 12:01PM
Tuesday, October 03, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Oct 3, 2023, 2:37PM
Monday, September 18, 2023
Overview Of Value Stocks In The Healthcare Sector
Benzinga Insights
-
Sep 18, 2023, 10:43AM
Tuesday, September 05, 2023
4 Analysts Have This to Say About Spero Therapeutics
Benzinga Insights
-
Sep 5, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk
-
Sep 5, 2023, 6:15AM
Monday, August 14, 2023
HC Wainwright & Co. Maintains Buy Rating for Spero Therapeutics: Here's What You Need To Know
Benzinga Insights
-
Aug 14, 2023, 1:00PM
HC Wainwright & Co. Maintains Buy on Spero Therapeutics, Raises Price Target to $7
Benzinga Newsdesk
-
Aug 14, 2023, 6:22AM
Thursday, August 10, 2023
Spero Therapeutics Q2 EPS $(0.23) Beats $(0.34) Estimate, Sales $2.72M Beat $1.07M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 4:45PM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Wednesday, August 09, 2023
Spero Therapeutics's Earnings: A Preview
Benzinga Insights
-
Aug 9, 2023, 1:02PM
Tuesday, August 01, 2023
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Aug 1, 2023, 6:22AM
Monday, July 31, 2023
Spero Therapeutics shares are trading higher after the company announced a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr.
Benzinga Newsdesk
-
Jul 31, 2023, 12:51PM
Spero Therapeutics Announces Special Protocol Assessment Agreement With FDA For Phase 3 PIVOT-PO Trial Of Tebipenem HBr
Benzinga Newsdesk
-
Jul 31, 2023, 8:07AM
Thursday, July 20, 2023
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Jul 20, 2023, 6:40AM
Wednesday, June 14, 2023
Spero Therapeutics Appoints Sath Shukla As President & Chief Executive Officer, To Be Effective August 1, 2023
Benzinga Newsdesk
-
Jun 14, 2023, 8:11AM
Thursday, May 11, 2023
Recap: Spero Therapeutics Q1 Earnings
Benzinga Insights
-
May 11, 2023, 4:15PM
Spero Therapeutics Q1 EPS $(0.25) Beats $(0.33) Estimate, Sales $2.07M Beat $1.00M Estimate
Benzinga Newsdesk
-
May 11, 2023, 4:10PM
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Wednesday, May 10, 2023
Spero Therapeutics's Earnings Outlook
Benzinga Insights
-
May 10, 2023, 2:02PM
Monday, April 10, 2023
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Apr 10, 2023, 9:40AM
Thursday, March 30, 2023
Spero Therapeutics Q4 EPS $0.55 Beats $0.04 Estimate, Sales $47.44M Beat $22.87M Estimate
Michael Horton
-
Mar 30, 2023, 4:21PM
Earnings Scheduled For March 30, 2023
Benzinga Insights
-
Mar 30, 2023, 7:24AM
Wednesday, March 29, 2023
Spero Therapeutics's Earnings: A Preview
Benzinga Insights
-
Mar 29, 2023, 11:02AM
Friday, March 10, 2023
Earnings Outlook For Spero Therapeutics
Benzinga Insights
-
Mar 10, 2023, 10:02AM
Monday, November 14, 2022
Spero Therapeutics Q3 EPS $(0.33) Misses $(0.30) Estimate, Sales $2.01M Miss $5.42M Estimate
Michael Horton
-
Nov 14, 2022, 4:16PM
Earnings Scheduled For November 14, 2022
Benzinga Insights
-
Nov 14, 2022, 5:06AM
Friday, November 11, 2022
Earnings Outlook For Spero Therapeutics
Benzinga Insights
-
Nov 11, 2022, 3:50PM
Tuesday, November 08, 2022
Spero Therapeutics Announces Closing Of Exclusive License Agreement With GSK For Tebipenem HBr
Benzinga Newsdesk
-
Nov 8, 2022, 8:19AM
Monday, October 10, 2022
How Is The Market Feeling About Spero Therapeutics?
Benzinga Insights
-
Oct 10, 2022, 10:09AM
Tuesday, October 04, 2022
EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank?
Chris Katje
-
Oct 4, 2022, 2:29PM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch